Info

3DM Inc. is a privately-held specialty biomaterials company, with a mission of developing novel medical therapies through its technologies for accelerating wound healing and tissue regeneration across a range of medical indications. 3DM Inc. has commercialized a revolutionary family of self-assembling nano-scale scaffolds, PuraMatrix, which has received numerous awards as a leading commercial synthetic scaffold for 3D cell culture in drug discovery, cancer biology, stem cell research and bioproduction. 3DM's medical devices provide a critical bridge in wound healing and tissue regeneration ,a resorbable injectable nano-scale scaffold to accelerate ingrowth of normal local tissue. 3DM's materials assemble upon injection into nanofibers, serving as a scaffold for tissue regeneration and able to deliver and release therapeutic proteins and stem cells in a localized area. Applications are focused on cardiovascular regeneration, accelerated cartilage and bone growth, protein drug delivery, and combinations with other medical devices. PuraMatrix solves important surgical problems. The materials self-assemble and gel upon injection, preventing back-leakage of injectate, providing hemostatic functionality, and controlling therapeutic delivery, while remaining compatible with minimally-invasive surgical tools. Advantages stem from the superior biocompatibility, physical properties and ease of combination with therapeutics and surgical techniques. 3DM is developing clinical products in orthopedic and cardiac medical devices in collaboration with many of the top medical device and regenerative medicine labs in the world. In October 2007, 3DM is accelerating its collaborations in the areas of orthopedic applications, cardiac devises, wound healing, drug and cell delivery, and so on. And together with this new parent company, 3DM has developed GMP grade PuraMatrixÔ and is now in the stage of Pre-clinical studies. 3DM will get into clinical study for the use of PuraMatrixÔ in the area of dental bone regeneration in the US in 2008.